License To Phase I Syk Inhibitor Brings Portola $36 Million Upfront
This article was originally published in The Pink Sheet Daily
Executive Summary
In a lucrative deal with Biogen Idec, Portola also gets a $9 million equity investment, up to $508.5 million in milestones and a co-promotion option, with Biogen assuming most of the development costs.